MARATTO

article · Bulletin of Egyptian Society for Physiological Sciences

Effect of the combination between empagliflozin and calcipotriol on cadmium-induced testicular toxicity in rats

20205 citationsOpen accessKafr el-Sheikh University

Abstract

The aim of this study was to assess the effect of empagliflozin and/or calcipotriol on cadmium-induced testicular toxicity in rats. Sixty male Wistar rats were divided into 6 equal groups: Control; cadmium; cadmium + empagliflozin; cadmium + calcipotriol; cadmium + Carboxymethyl cellulose and cadmium + empagliflozin + calcipotriol. Testicular enzymes, serum testosterone, luteinizing hormone and follicle stimulating hormone were measured. Also, testicular tissue antioxidant enzymes, interleukin-6 (IL-6), transforming growth factor beta 1 (TGF-β1) and sperm characteristics were determined. Parts of the testes were subjected to histopathological and immunohistochemical examination. Empagliflozin/calcipotriol combination restored the testicular enzymes, sperm characteristics, hormonal profile and the antioxidant defenses compared to the use of each of these drugs alone. Also, this combination significantly ameliorated the inflammatory processes and induced significant improvement of the histopathological, and immunohistochemical picture compared to the use of each of these drugs alone. So, empagliflozin/calcipotriol combination might represent a promising therapeutic modality for amelioration of cadmium-induced testicular toxicity.

Research topics

  • Heavy Metal Exposure and Toxicity

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/besps.2019.14918.1029

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.